1. Home
  2. MYO vs NSRX Comparison

MYO vs NSRX Comparison

Compare MYO & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myomo Inc.

MYO

Myomo Inc.

HOLD

Current Price

$1.07

Market Cap

44.8M

Sector

Health Care

ML Signal

HOLD

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$3.19

Market Cap

38.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MYO
NSRX
Founded
2004
2019
Country
United States
Israel
Employees
N/A
7
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.8M
38.9M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
MYO
NSRX
Price
$1.07
$3.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$7.67
$19.67
AVG Volume (30 Days)
317.1K
10.0K
Earning Date
05-08-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,000,000,000.00
N/A
Revenue This Year
$9.10
N/A
Revenue Next Year
$13.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40814.79
N/A
52 Week Low
$0.61
$1.98
52 Week High
$2.02
$9.99

Technical Indicators

Market Signals
Indicator
MYO
NSRX
Relative Strength Index (RSI) 51.71 52.32
Support Level $0.89 $2.83
Resistance Level $1.17 $3.60
Average True Range (ATR) 0.09 0.18
MACD 0.01 0.01
Stochastic Oscillator 73.07 78.93

Price Performance

Historical Comparison
MYO
NSRX

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: